Open Access

Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up

  • Authors:
    • Xiaohua Wang
    • Xiaoguang Yin
    • Wei Sun
    • Jin Bai
    • Yawen Shen
    • Qiang Ao
    • Yongquan Gu
    • Ying Liu
  • View Affiliations

  • Published online on: March 14, 2017     https://doi.org/10.3892/etm.2017.4229
  • Pages: 2255-2258
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Four patients with chronic refractory immune thrombocytopenic purpura (ITP) received human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). The hUC-MSC dose was 5x107 to 1x108. Complete remission (CR) was achieved in three patients in 12 months and one patient in 24 months. Three patients received the second hUC-MSC transplantation with the same dose. The median time between hUC-MSC transplantation and response was 12.5 days (range, 7-16). There were no severe adverse events during and post hUC-MSC transplantation. During follow-up (median, 17 months; range, 13-24) no other immuno­suppressive drugs were used post‑first hUC-MSCs transplantation. In conclusion, hUC-MSC transplantation is a reasonable salvage treatment in chronic refractory ITP. Prospective randomized large-scale clinical trials are needed to further elucidate the efficacy of hUC-MSCs transplantation therapy on ITP.
View Figures
View References

Related Articles

Journal Cover

May-2017
Volume 13 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang X, Yin X, Sun W, Bai J, Shen Y, Ao Q, Gu Y and Liu Y: Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up. Exp Ther Med 13: 2255-2258, 2017
APA
Wang, X., Yin, X., Sun, W., Bai, J., Shen, Y., Ao, Q. ... Liu, Y. (2017). Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up. Experimental and Therapeutic Medicine, 13, 2255-2258. https://doi.org/10.3892/etm.2017.4229
MLA
Wang, X., Yin, X., Sun, W., Bai, J., Shen, Y., Ao, Q., Gu, Y., Liu, Y."Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up". Experimental and Therapeutic Medicine 13.5 (2017): 2255-2258.
Chicago
Wang, X., Yin, X., Sun, W., Bai, J., Shen, Y., Ao, Q., Gu, Y., Liu, Y."Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up". Experimental and Therapeutic Medicine 13, no. 5 (2017): 2255-2258. https://doi.org/10.3892/etm.2017.4229